

Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 16, 2012.

A. Federal Reserve Bank of Minneapolis (Jacqueline G. King, Community Affairs Officer) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291:

1. Thomas Watson, Grand Forks, North Dakota, as an individual and as trustee, and Thomas Watson and Toby Kommer, Fargo, North Dakota, as trustees of the Bank Forward Employee Stock Ownership Plan, Hannaford, North Dakota ("ESOP"), to acquire control of Security State Bank Holding Company, Fargo, North Dakota ("Company"), and thereby indirectly acquire control of Bank Forward, Hannaford, North Dakota. In addition, Mr. Watson and Mr. Kommer, and the ESOP, have applied as a group acting in concert to control Company.

Board of Governors of the Federal Reserve System, June 29, 2012.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 2012–16483 Filed 7–5–12; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Designation of a Class of Employees for Addition to the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HHS gives notice of a decision to designate a class of employees from the Feed Materials Production Center (FMPC) in Fernald, Ohio, also known as the Fernald Environmental Management Project (FEMP), as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness

Compensation Program Act of 2000. On June 27, 2012, the Secretary of HHS designated the following class of employees as an addition to the SEC:

All employees of DOE, DOE contractors, or subcontractors who worked at all locations at the Feed Materials Production Center (FMPC) in Fernald, Ohio, also known as the Fernald Environmental Management Project (FEMP), from January 1, 1968, through December 31, 1978, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in combination with work days within the parameters established for one or more classes of employees included in the Special Exposure Cohort.

This designation will become effective on July 27, 2012, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the **Federal Register** reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC.

FOR FURTHER INFORMATION CONTACT:

Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 1–877–222–7570. Information requests can also be submitted by email to *DCAS@ CDC.GOV*.

John Howard.

Director, National Institute for Occupational Safety and Health.

[FR Doc. 2012-16591 Filed 7-5-12; 8:45 am]

BILLING CODE 4150-28-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS. **ACTION:** Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Sinae Kim, Ph.D., Emory University: Based on the report of an investigation conducted by Emory University (EU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Sinae Kim, former Postdoctoral Fellow, Department of Medicine, EU, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL079137, R01 HL084471, and R03 HL096325, and National Institute of General Medical Sciences (NIGMS), NIH, grant RC1 GM092035.

FOR FURTHER INFORMATION CONTACT: John Dahlberg, Ph.D., Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

SUPPLEMENTARY INFORMATION: ORI found that the Respondent engaged in research misconduct by falsifying data that were included in five (5) manuscripts submitted in 2009 for publication to Blood, Nature, Nature Biotechnology, Nature Medicine, and Science, one (1) poster presented at the 2009 American Heart Association (AHA) meeting, four (4) laboratory meeting presentations, one (1) image file, three (3) funded NIH grants (RC1 GM092035, R01 HL079137, and R03 HL096325), and five (5) submitted NIH grant applications (RC1 HL100648-01, RC2 HL101600-01, RC4 HL106748-01, R01 HD067130-01, and U01 HL107444-01). The manuscripts submitted in 2009 were not accepted for publication.

Specifically, ORI finds that the Respondent knowingly and intentionally:

- 1. Falsified three (3) figures for immunocytochemistry and alkaline phosphtase (AP) staining images, karyotyping and real-time reverse transcription polymerase chain reaction (RT–PCR) results by using experimental results from her prior work in Korea with human embryonic stem cells (hESCs) to confirm the generation, differentiation, and verification of human induced pluripotent stem cells (iPSCs). The false data were included in:
- a. Figures 1c and 2i (panels #4 & 13) in the Nature 2009, Science 2009, and Nature Biotechnology 2009 manuscripts and Supplementary Figure 4 in the Nature 2009 manuscript
- b. Supplementary Figure 5 in the *Nature Biotechnology* 2009 manuscript
- c. Figures S1B and S1D (panels #4 & 13) in the Blood 2009 manuscript
- d. Supplementary Figures 8B and 8D (panels #4 & 13) in the *Nature Medicine* 2009 manuscript
- e. Figure 9 in the RC1 GM092035 grant f. Figure 8 in the R01 HL079137 grant
- g. Figure 2 in the RC1 HL100648 grant
- h. Figure 8 in the RC2 HL101600 grant
- i. Figure 3 in the R01 HD067130 grant
- j. Figure 1 in the RC4 HL106748 grant k. Figures 1C, 1H, and 1I (panel #3) in the R03 HL096325 grant
- l. Figure 5 in the U01 HL107444 grant m. Figures 2C and 3I (panels #4 & 13) in the poster presented at the 2009 AHA meeting
- n. The presentations 'Figures_Sinae Kim_120808.ppt' and 'Figures_Sinae Kim_121508.ppt'